PCSK9 Inhibitors’ LDL-Cholesterol Lowering Ability Saves Lives

Adding this drug to statin and ezetimibe therapy drops LDL cholesterol to very low levels, further preventing heart attacks and strokes.

By
estaff
-
Published:
0
© skynesher | Getty Images When traditional cholesterol medications fail to lower LDL cholesterol levels far enough to protect against a heart attack, adding a PCSK9 inhibitor may be just what the doctor ordered.

Cholesterol-lowering drugs known as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors may not be well-known, but when added to statin therapy they provide powerful protection for individuals at high risk of heart attack and stroke.

To continue reading this article or issue you must be a paid subscriber. Sign in
Subscribe

Subscribe to Heart Advisor

Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access

RELATED ARTICLESMORE FROM AUTHOR